Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Liver Neoplasms 1Hepatic Metastasis of Colorectal Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

Gemcitabine 13Cisplatin 10pembrolizumab 7Oxaliplatin 5Leucovorin 5Fluorouracil 5durvalumab 4Paclitaxel 4Nivolumab 3Injections 3Immune Checkpoint Inhibitors 3Capecitabine 3camrelizumab 2Docetaxel 2Cetuximab 2Carboplatin 2130-nm albumin-bound paclitaxel 2tremelimumab 1surufatinib 1spartalizumab 1silmitasertib 1regorafenib 1pertuzumab 1manganese chloride 1lenvatinib 1irinotecan sucrosofate 1folfirinox 1devimistat 1derazantinib 1binimetinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Biliary Tract Neoplasms × Radiofrequency Ablation × Clear all
NCT01853618 2019-12-10

Tremelimumab With Chemoembolization or Ablation for Liver Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
61 enrolled 18 charts
Gastrointestinal

Biliary Tract Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡